From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Tom Winnifrith Bearcast, Jim Mellon, SalvaRx and the lessons from the todger spray episode

By Tom Winnifrith | Thursday 16 August 2018


Disclosure: Financial Investigative Media Limited, which is not owned by Tom Winnifrith but by a trust for his dependants, owns shares in companies mentioned in this article. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


In today's delayed podcast I look at the lessons for SalvaRx (SALV) from the Plethora (PLE) & Regent Pacific episode and ask what is happening at Regent as its shares continue to slide? I also look at the increasingly confused picture at Online Blockchain (OBC) and then ponder why CEO's should not be a guide to share prices or when to sell, ref Optibiotx (OPTI), noting also today's events at Skinbiotherapeutics (SBTX)

You must be a paid subscriber to listen to Bearcast
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

CTAI

Catenai – monster dilution

Time left: 03:49:45